FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083580024> ?p ?o ?g. }

• W3083580024 abstract "Background: Although bevacizumab (BVZ) is no longer unanimously recommended in the management of breast cancer (BRCA), few patients have shown objective benefit under BVZ treatment. We thus hypothesized that individual characteristics (germinal polymorphisms, SNPs) might help to subgroup patients drawing benefit from this therapy. We herein report confirmation of a preliminary pharmacogenetic ancillary study (ASCO 2017, abstract #1079) in the prospective COMET trial conducted on metastatic BRCA patients receiving first-line BVZ associated with paclitaxel. Both the number of patients (203 to 306) and median follow-up (24 to 50 months) were markedly increased. Methods: Patients were enrolled in the COMET prospective cohort study from 2012 to 2015. Germinal DNA was analyzed by high-throughput genotyping in 306 patients using an 18 SNPs panel covering 7 objectively preselected genes (VEGFA, VEGFR1, VEGFR2, CYP450, CYP2C8, ABCB1, IL8). Dominant and recessive models were investigated to test possible associations between SNPs and Progression-Free Survival (PFS) and Overall Survival (OS) with a median follow-up of 50 months (CI95%: 47-57). In multivariate analysis, association between clinical characteristics, SNPs and PFS or OS was expressed as a hazard ratio (HR) with a 95% confidence interval, which was estimated using a Cox proportional-hazards model. P values ≤ 0.05 were considered statistically significant. Computational analysis using a GTEX portal was used to determine potential eQTL (expression Quantitative Trait Loci) in tissues. Results: Median age was 55.5 (28-80), 80% ductal carcinoma, with a majority (57%) of histological grade equal to I or II. In multivariate Cox analysis, histological grade III and rs833061 C/C (VEGF-A) were associated with shorter PFS (HR= 1.7, 95%CI [1.3-2.1], p Conclusions: Using an easy-to-perform, low-cost genotyping test, germinal DNA identified predictors for BVZ-based treatment outcome in metastatic BRCA patients. These results open up the possibility of reconsidering BVZ treatment in a defined subgroup of BRCA patients. Citation Format: Gerard Milano, Jocelyn Gal, Patrick Brest, Nathalie Ebran, Laurence Llorca, Coraline Dubot, Gilles Romieu, Isabelle Desmoulins, Etienne Brain, Anthony Goncalves, Jean-Marc Ferrero, Paul Cottu, Marc Debled, Olivier Tredan, Emmanuel Chamorey, Marco Carlo Merlano, Jerome Lemonnier. VEGFA and VEGFR2 SNPs identify a subgroup of breast cancer patients with favorable outcome under Bevacizumab-based therapy - A message from COMET, a French Unicancer multicentric study [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4291." @default.
• W3083580024 created "2020-09-11" @default.
• W3083580024 creator A5006642161 @default.
• W3083580024 creator A5015046932 @default.
• W3083580024 creator A5019336103 @default.
• W3083580024 creator A5020487290 @default.
• W3083580024 creator A5023675047 @default.
• W3083580024 creator A5026275112 @default.
• W3083580024 creator A5028395175 @default.
• W3083580024 creator A5032686530 @default.
• W3083580024 creator A5034058277 @default.
• W3083580024 creator A5035439475 @default.
• W3083580024 creator A5036521399 @default.
• W3083580024 creator A5052876034 @default.
• W3083580024 creator A5073011726 @default.
• W3083580024 creator A5082215736 @default.
• W3083580024 creator A5084253341 @default.
• W3083580024 creator A5090050048 @default.
• W3083580024 creator A5090608495 @default.
• W3083580024 date "2020-08-13" @default.
• W3083580024 modified "2023-10-18" @default.
• W3083580024 title "Abstract 4291: VEGFA and VEGFR2 SNPs identify a subgroup of breast cancer patients with favorable outcome under Bevacizumab-based therapy - A message from COMET, a French Unicancer multicentric study" @default.
• W3083580024 doi "https://doi.org/10.1158/1538-7445.am2020-4291" @default.
• W3083580024 hasPublicationYear "2020" @default.
• W3083580024 type Work @default.
• W3083580024 sameAs 3083580024 @default.
• W3083580024 citedByCount "0" @default.
• W3083580024 crossrefType "proceedings-article" @default.
• W3083580024 hasAuthorship W3083580024A5006642161 @default.
• W3083580024 hasAuthorship W3083580024A5015046932 @default.
• W3083580024 hasAuthorship W3083580024A5019336103 @default.
• W3083580024 hasAuthorship W3083580024A5020487290 @default.
• W3083580024 hasAuthorship W3083580024A5023675047 @default.
• W3083580024 hasAuthorship W3083580024A5026275112 @default.
• W3083580024 hasAuthorship W3083580024A5028395175 @default.
• W3083580024 hasAuthorship W3083580024A5032686530 @default.
• W3083580024 hasAuthorship W3083580024A5034058277 @default.
• W3083580024 hasAuthorship W3083580024A5035439475 @default.
• W3083580024 hasAuthorship W3083580024A5036521399 @default.
• W3083580024 hasAuthorship W3083580024A5052876034 @default.
• W3083580024 hasAuthorship W3083580024A5073011726 @default.
• W3083580024 hasAuthorship W3083580024A5082215736 @default.
• W3083580024 hasAuthorship W3083580024A5084253341 @default.
• W3083580024 hasAuthorship W3083580024A5090050048 @default.
• W3083580024 hasAuthorship W3083580024A5090608495 @default.
• W3083580024 hasConcept C121608353 @default.
• W3083580024 hasConcept C126322002 @default.
• W3083580024 hasConcept C143998085 @default.
• W3083580024 hasConcept C144237770 @default.
• W3083580024 hasConcept C148220186 @default.
• W3083580024 hasConcept C167734588 @default.
• W3083580024 hasConcept C2776694085 @default.
• W3083580024 hasConcept C2777802072 @default.
• W3083580024 hasConcept C33923547 @default.
• W3083580024 hasConcept C530470458 @default.
• W3083580024 hasConcept C71924100 @default.
• W3083580024 hasConcept C86803240 @default.
• W3083580024 hasConcept C87355193 @default.
• W3083580024 hasConcept C94081185 @default.
• W3083580024 hasConceptScore W3083580024C121608353 @default.
• W3083580024 hasConceptScore W3083580024C126322002 @default.
• W3083580024 hasConceptScore W3083580024C143998085 @default.
• W3083580024 hasConceptScore W3083580024C144237770 @default.
• W3083580024 hasConceptScore W3083580024C148220186 @default.
• W3083580024 hasConceptScore W3083580024C167734588 @default.
• W3083580024 hasConceptScore W3083580024C2776694085 @default.
• W3083580024 hasConceptScore W3083580024C2777802072 @default.
• W3083580024 hasConceptScore W3083580024C33923547 @default.
• W3083580024 hasConceptScore W3083580024C530470458 @default.
• W3083580024 hasConceptScore W3083580024C71924100 @default.
• W3083580024 hasConceptScore W3083580024C86803240 @default.
• W3083580024 hasConceptScore W3083580024C87355193 @default.
• W3083580024 hasConceptScore W3083580024C94081185 @default.
• W3083580024 hasLocation W30835800241 @default.
• W3083580024 hasOpenAccess W3083580024 @default.
• W3083580024 hasPrimaryLocation W30835800241 @default.
• W3083580024 hasRelatedWork W144521535 @default.
• W3083580024 hasRelatedWork W1978900889 @default.
• W3083580024 hasRelatedWork W2253184406 @default.
• W3083580024 hasRelatedWork W2288683100 @default.
• W3083580024 hasRelatedWork W2411890706 @default.
• W3083580024 hasRelatedWork W2512704243 @default.
• W3083580024 hasRelatedWork W2602911552 @default.
• W3083580024 hasRelatedWork W2898481592 @default.
• W3083580024 hasRelatedWork W377899687 @default.
• W3083580024 hasRelatedWork W4240544598 @default.
• W3083580024 isParatext "false" @default.
• W3083580024 isRetracted "false" @default.
• W3083580024 magId "3083580024" @default.
• W3083580024 workType "article" @default.